Plain-English translation of NCT06907017 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is one of the first times this treatment has been tested in people.
This is the first study in humans testing the CorWave LVAS, a mechanical heart pump designed to help patients with advanced heart failure. The pump is implanted surgically into your heart to take over pumping blood when your own heart can no longer do the job effectively. Researchers want to learn whether this new device is safe and whether it helps patients live longer and feel better.
Advanced heart failure is a serious condition where the heart severely weakens and standard medications stop working. This trial exists to see if the CorWave LVAS can give patients a better option—either to help them survive longer while waiting for a heart transplant, or potentially as a longer-term solution.
You likely qualify if…
You likely don't qualify if…
If you qualify and are enrolled, you will undergo heart surgery to have the CorWave LVAS implanted. After surgery, you will need to make regular visits to the study center so doctors can monitor how well the device is working, how you're feeling, and manage any complications. You will also need to take blood-thinning medications and follow strict guidelines for device care and monitoring at home. The study will follow you for an extended period to assess whether the pump helps you live longer and improves your quality of life.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Australia
Sponsor
CorWave
Enrollment target
~20 participants
Started
May 2025
Primary completion
May 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gabriella Giaquinta
CorWave
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.